Lyell Immunopharma, Inc.
For the period ended May 6, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 6, 2026 · Filed May 6, 2026
Use the contents to explore the available documents and sections.
LYEL$14.86-0.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Statement of Operations Data:
Statement of Operations Data:
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $2 | $7 |
| Operating expenses: | ||
| Research and development | 36,604 | 43,447 |
| General and administrative | 9,555 | 14,046 |
| Other operating income, net | (1,896) | (119) |
| Total operating expenses | 44,263 | 57,374 |
| Loss from operations | (44,261) | (57,367) |
| Interest income, net | 2,194 | 3,862 |
| Other income, net | 17,914 | 1,310 |
| Total other income, net | 20,108 | 5,172 |
| Net loss | $(24,153) | $(52,195) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.